Latozinemab (anti-Sortilin) 是一种重组人源化抗 Sortilin 单克隆抗体。Latozinemab (anti-Sortilin) 以高亲和力有效结合 Sortilin,并阻断颗粒蛋白前体 (PGRN) 和 Sortilin 受体之间的相互作用。Latozinemab (anti-Sortilin) 具有引起额颞叶痴呆 (FTD) (FTD-GRN) 研究的颗粒蛋白原基因 (GRN) 突变的潜力。
Latozinemab (anti-Sortilin) is a recombinant humanized anti-Sortilin monoclonal antibody. Latozinemab (anti-Sortilin) effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab (anti-Sortilin) has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg